Blueprint Medicines Corporation
Blueprint Medicines Corporation Fundamental Analysis
Blueprint Medicines Corporation (BPMC) shows weak financial fundamentals with a PE ratio of -77.87, profit margin of -24.94%, and ROE of -33.25%. The company generates $0.4B in annual revenue with weak year-over-year growth of 1.04%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -7.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BPMC's fundamental strength across five key dimensions:
Efficiency Score
WeakBPMC struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBPMC trades at attractive valuation levels.
Growth Score
ModerateBPMC shows steady but slowing expansion.
Financial Health Score
ExcellentBPMC maintains a strong and stable balance sheet.
Profitability Score
WeakBPMC struggles to sustain strong margins.
Key Financial Metrics
Is BPMC Expensive or Cheap?
P/E Ratio
BPMC trades at -77.87 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BPMC's PEG of 0.56 indicates potential undervaluation.
Price to Book
The market values Blueprint Medicines Corporation at 24.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -82.31 times EBITDA. This is generally considered low.
How Well Does BPMC Make Money?
Net Profit Margin
For every $100 in sales, Blueprint Medicines Corporation keeps $-24.94 as profit after all expenses.
Operating Margin
Core operations generate -30.96 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-33.25 in profit for every $100 of shareholder equity.
ROA
Blueprint Medicines Corporation generates $-8.84 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Blueprint Medicines Corporation generates limited operating cash flow of $-98.99M, signaling weaker underlying cash strength.
Free Cash Flow
Blueprint Medicines Corporation generates weak or negative free cash flow of $-101.82M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.58 in free cash annually.
FCF Yield
BPMC converts -1.20% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-77.87
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.56
vs 25 benchmark
P/B Ratio
Price to book value ratio
24.07
vs 25 benchmark
P/S Ratio
Price to sales ratio
19.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.36
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.80
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.33
vs 25 benchmark
ROA
Return on assets percentage
-0.09
vs 25 benchmark
ROCE
Return on capital employed
-0.14
vs 25 benchmark
How BPMC Stacks Against Its Sector Peers
| Metric | BPMC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -77.87 | 29.28 | Better (Cheaper) |
| ROE | -33.25% | 820.00% | Weak |
| Net Margin | -24.94% | -19731.00% (disorted) | Weak |
| Debt/Equity | 0.36 | 0.26 | Weak (High Leverage) |
| Current Ratio | 2.80 | 4.69 | Strong Liquidity |
| ROA | -8.84% | -17993.00% (disorted) | Weak |
BPMC outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Blueprint Medicines Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
482.11%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
84.47%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
47.29%
Industry Style: Defensive, Growth, Innovation
High Growth